Transcript An Introduction to Personalised Medicine and Health

Diagnostic Evidence
Co-operative Leeds
An introduction to personalised
medicine & health in Leeds
Michael Messenger, Deputy Director NIHR DEC Leeds
A partnership between the NHS, patients, academia, industry and charities
A Vision for Leeds
Data storage
Data linkage
Better Actions,
Outcomes &
Affordability
Healthcare
data
acquisition
Metadata
(Quality &
Accuracy)
Improving Patient-Clinician
decision making (> accuracy,
tailoring, timing, participation)
Effective
Communication
Analysis and
interpretation
The Personalised Health & Care
Journey
Prediction &
Prevention
Early Diagnosis
Disease
Screening
Prognosis
Molecular
Phenotyping
Treatment benefit /
response
Monitoring
Recovery
Death
Hospital
admission
Hospital
discharge
Disease Free
Symptomatic
Disease
Asymptomatic
Disease
Acute
disease
diagnosed
Disease
response
Treatment
initiation
Shift towards individualised prevention
Chronic
disease
relapse
Late sideeffects
Translational
Gap 1
Translational
Gap 2
Centre for Personalised Medicine
and Health
Establish the evidence base to accelerate PM technologies into
routine clinical practice
“The Push”
New Technology
• Drugs
• Devices
• Diagnostics
Early Modelling
(Commercial and
NHS opportunity)
•
•
•
•
“The Pull”
Clinical Need
NHS
Academia
Industry
Stakeholders
Precision Medicine Research Infrastructure
Patient Cohorts, Biobanks, “Big Data”, Analytical Platforms (e.g. Omics), High
Performance Computing
Patient
Benefit
Preclinical &
Measurement
Validity
Safety &
Clinical
Validity
Clinical
Efficacy &
Utility
CostEffectiveness &
Market Approval
Dissemination&
Adoption
Economic
Value
Methodological expertise
Health Economics, Health Informatics, Medical Statistics, Metrology, Systems
Biology, Quality Management, Artificial Intelligence